William J. H. Griffiths
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William J. H. Griffiths has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Adam Duckworth
Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
6 shared publicationsDinakantha S. Kumararatne
Department of Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
4 shared publications- Vian Azzu
The Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Level 5 Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
4 shared publications Lucinda Kennard
Departments of Allergy & Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
3 shared publicationsMeha Bhuva
Cambridge Liver Unit, Cambridge University Hospitals, Cambridge, UK
3 shared publicationsRebecca Brais
Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
3 shared publications
Latest Publications
- 28 June 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (10) , 5137-5151
Genetic Analysis of Isolated Hepatic Ductal Plate Malformation Reveals Novel Variants and Insights into Phenotypic Correlation
Polycystic liver disease and other manifestations of ductal plate malformation (DPM) may be incidental or indeed develop significant complications. The genetic basis of 'isolated' DPM differs from that associated with polycystic kidney disease and remains incompletely understood. We sought to genetically characterize a sizeable single-center cohort of patients with 'isolated' DPM, defined as absence of polycystic kidney disease. 55 consecutive patients with isolated DPM were analyzed retrospectively with next-generation sequencing used to identify genetic variants. 54/55 completed genetic characterization. 40 patients had polycystic liver disease (PCLD) as the primary phenotype, 9 had congenital hepatic fibrosis (CHF), 1 had Caroli disease and 5 had multiple biliary hamartomas. 10 patients had mixed phenotype. The majority were female (78%) and mean age at presentation was 47 years. Of patients with PCLD, previous estrogen exposure was associated with cyst complications. Of the 54 genetically analyzed patients, pathogenic or likely pathogenic variants were identified in 31. PCLD was mainly associated with SEC63, PRKCSH and GANAB heterozygous variants with a minor contribution from PKHD1 and ALG8. PRKCSH followed by GANAB was associated with the most severe PCLD presentation. CHF was represented solely by PKHD1 variants half of which were missense, as opposed to truncating in all but one of the other genotypes. Importantly, 5 novel variants were identified (4 SEC63, 1 PRKCSH). We have shown that current genetic testing methods are often revealing in isolated DPM. Future broadening of genetic analysis will enhance diagnosis and understanding within this heterogeneous disease spectrum.
- 28 June 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (10) , 5137-5151
Genetic Analysis of Isolated Hepatic Ductal Plate Malformation Reveals Novel Variants and Insights into Phenotypic Correlation
Polycystic liver disease and other manifestations of ductal plate malformation (DPM) may be incidental or indeed develop significant complications. The genetic basis of 'isolated' DPM differs from that associated with polycystic kidney disease and remains incompletely understood. We sought to genetically characterize a sizeable single-center cohort of patients with 'isolated' DPM, defined as absence of polycystic kidney disease. 55 consecutive patients with isolated DPM were analyzed retrospectively with next-generation sequencing used to identify genetic variants. 54/55 completed genetic characterization. 40 patients had polycystic liver disease (PCLD) as the primary phenotype, 9 had congenital hepatic fibrosis (CHF), 1 had Caroli disease and 5 had multiple biliary hamartomas. 10 patients had mixed phenotype. The majority were female (78%) and mean age at presentation was 47 years. Of patients with PCLD, previous estrogen exposure was associated with cyst complications. Of the 54 genetically analyzed patients, pathogenic or likely pathogenic variants were identified in 31. PCLD was mainly associated with SEC63, PRKCSH and GANAB heterozygous variants with a minor contribution from PKHD1 and ALG8. PRKCSH followed by GANAB was associated with the most severe PCLD presentation. CHF was represented solely by PKHD1 variants half of which were missense, as opposed to truncating in all but one of the other genotypes. Importantly, 5 novel variants were identified (4 SEC63, 1 PRKCSH). We have shown that current genetic testing methods are often revealing in isolated DPM. Future broadening of genetic analysis will enhance diagnosis and understanding within this heterogeneous disease spectrum.
- Open Access
- 26 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (5) , 1522-1536
Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations
The transcription factor IKAROS plays an important role in lymphocyte development, differentiation, and as a tumor suppressor. To date, >70 IKAROS germ line heterozygous variants have been reported in patients with primary immunodeficiency (PID)/inborn errors of immunity (IEI) and leukemia, and this number continues to grow. Germ line IKAROS loss- and gain-of-function mutations have been linked to immunodeficiency, immune dysregulation, and hematologic malignancies, with a broad spectrum of clinical manifestations. Routine next-generation sequencing approaches in patients with PID/IEI have facilitated the identification of IKAROS variants, including several cases with variants of uncertain significance (VUS). To determine the VUS’ functional behavior, we systematically generated constructs recapitulating those changes and tested IKAROS functions in vitro. We also conducted an in-depth examination of the C-terminal dimerization domain using alanine-scanning mutagenesis to identify amino acids critical for dimerization and other functions. This work provides a comprehensive description of the biologic impact of 81 previously unreported and/or untested IKAROS variants, including 33 patient-detected germ line VUS and 48 laboratory-generated mutations in the dimerization domain. Among them, 15 of the patient-detected variants, primarily mapping to IKAROS DNA-binding or dimerization domains, and at least 21 of the laboratory-generated mutations, impaired IKAROS function and could explain or result in human disease. VUS located in between IKAROS DNA binding and dimerization domains were less likely to be functionally deleterious. Of note, both positive and negative functional data herein generated can be relevant for patients carrying these IKAROS variants, helping to establish a diagnosis and guide treatment decisions.
- 26 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (5) , 1522-1536
Open AccessSystematic functional validation of IKAROS variants from patients and laboratory-generated mutations
The transcription factor IKAROS plays an important role in lymphocyte development, differentiation, and as a tumor suppressor. To date, >70 IKAROS germ line heterozygous variants have been reported in patients with primary immunodeficiency (PID)/inborn errors of immunity (IEI) and leukemia, and this number continues to grow. Germ line IKAROS loss- and gain-of-function mutations have been linked to immunodeficiency, immune dysregulation, and hematologic malignancies, with a broad spectrum of clinical manifestations. Routine next-generation sequencing approaches in patients with PID/IEI have facilitated the identification of IKAROS variants, including several cases with variants of uncertain significance (VUS). To determine the VUS’ functional behavior, we systematically generated constructs recapitulating those changes and tested IKAROS functions in vitro. We also conducted an in-depth examination of the C-terminal dimerization domain using alanine-scanning mutagenesis to identify amino acids critical for dimerization and other functions. This work provides a comprehensive description of the biologic impact of 81 previously unreported and/or untested IKAROS variants, including 33 patient-detected germ line VUS and 48 laboratory-generated mutations in the dimerization domain. Among them, 15 of the patient-detected variants, primarily mapping to IKAROS DNA-binding or dimerization domains, and at least 21 of the laboratory-generated mutations, impaired IKAROS function and could explain or result in human disease. VUS located in between IKAROS DNA binding and dimerization domains were less likely to be functionally deleterious. Of note, both positive and negative functional data herein generated can be relevant for patients carrying these IKAROS variants, helping to establish a diagnosis and guide treatment decisions.
- 17 March 2023
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (6) , 2704-2709
Magnetic Resonance Liver Iron Concentration Can Guide Venesection Decision-Making in Hyperferritinemia
Background The clinical benefit of venesection in suspected iron overload can be unclear and serum ferritin may overestimate the degree of iron overload. Aims To help inform practice, we examined magnetic resonance liver iron concentration (MRLIC) in a cohort investigated for haemochromatosis. Methods One hundred and six subjects with suspected haemochromatosis underwent HFE genotyping and MRLIC with time-matched serum ferritin and transferrin saturation values. For those treated with venesection, volume of blood removed was calculated as a measure of iron overload. Results Forty-seven C282Y homozygotes had median ferritin 937 µg/l and MRLIC 4.83 mg/g; MRLIC was significantly higher vs non-homozygotes for any given ferritin concentration. No significant difference in MRLIC was observed between homozygotes with and without additional risk factors for hyperferritinemia. Thirty-three compound heterozygotes (C282Y/H63D) had median ferritin 767 µg/l and MRLIC 2.58 mg/g; ferritin < 750 µg/l showed 100% specificity for lack of significant iron overload (< 3.2 mg/g). 79% of C282Y/H63D had additional risk factors—mean MRLIC was significantly lower in this sub-group (2.4 mg/g vs 3.23 mg/g). 26 C282Y heterozygous or wild-type had median ferritin 1226 µg/l and MRLIC 2.13 mg/g; 69% with additional risk factors had significantly higher ferritin concentrations (with comparable MRLIC) and ferritin < 1000 µg/l showed 100% specificity for lack of significant iron overload. In 31 patients (26 homozygotes, 5 C282Y/H63D) venesected to ferritin < 100 µg/l, MRLIC and total venesection volume correlated strongly (r = 0.749), unlike MRLIC and serum ferritin. Conclusion MRLIC is an accurate marker of iron overload in haemochromatosis. We propose serum ferritin thresholds in non-homozygotes which, if validated, could tailor cost-effective use of MRLIC in venesection decision-making.
- 17 March 2023
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (6) , 2704-2709
Magnetic Resonance Liver Iron Concentration Can Guide Venesection Decision-Making in Hyperferritinemia
Background The clinical benefit of venesection in suspected iron overload can be unclear and serum ferritin may overestimate the degree of iron overload. Aims To help inform practice, we examined magnetic resonance liver iron concentration (MRLIC) in a cohort investigated for haemochromatosis. Methods One hundred and six subjects with suspected haemochromatosis underwent HFE genotyping and MRLIC with time-matched serum ferritin and transferrin saturation values. For those treated with venesection, volume of blood removed was calculated as a measure of iron overload. Results Forty-seven C282Y homozygotes had median ferritin 937 µg/l and MRLIC 4.83 mg/g; MRLIC was significantly higher vs non-homozygotes for any given ferritin concentration. No significant difference in MRLIC was observed between homozygotes with and without additional risk factors for hyperferritinemia. Thirty-three compound heterozygotes (C282Y/H63D) had median ferritin 767 µg/l and MRLIC 2.58 mg/g; ferritin < 750 µg/l showed 100% specificity for lack of significant iron overload (< 3.2 mg/g). 79% of C282Y/H63D had additional risk factors—mean MRLIC was significantly lower in this sub-group (2.4 mg/g vs 3.23 mg/g). 26 C282Y heterozygous or wild-type had median ferritin 1226 µg/l and MRLIC 2.13 mg/g; 69% with additional risk factors had significantly higher ferritin concentrations (with comparable MRLIC) and ferritin < 1000 µg/l showed 100% specificity for lack of significant iron overload. In 31 patients (26 homozygotes, 5 C282Y/H63D) venesected to ferritin < 100 µg/l, MRLIC and total venesection volume correlated strongly (r = 0.749), unlike MRLIC and serum ferritin. Conclusion MRLIC is an accurate marker of iron overload in haemochromatosis. We propose serum ferritin thresholds in non-homozygotes which, if validated, could tailor cost-effective use of MRLIC in venesection decision-making.
- 5 November 2022
- Published by Springer Nature
- p. 245-259
Hereditary Haemochromatosis
- 4 April 2022
- Published by Elsevier in Transplant Immunology
- Vol. 72, 101600
First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination
- 4 April 2022
- Published by Elsevier in Transplant Immunology
- Vol. 72, 101600
First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination
- 14 March 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (12) , 5551-5561
ABCB4 Mutations in Adults Cause a Spectrum Cholestatic Disorder Histologically Distinct from Other Biliary Disease
Background Mutations in the ABCB4 gene are associated with failure of bile acid emulsification leading to cholestatic liver disease. Presentations range from progressive familial intrahepatic cholestasis type 3 (PFIC3) in childhood, to milder forms seen in adulthood. Aims We sought to characterize adult disease with particular reference to histology which has been hitherto poorly defined. Methods Four unrelated adults (three female, mean age 39 years) and three sisters presenting with cholestatic liver disease in adulthood, associated with variants in the ABCB4 gene, were identified. Clinical review and detailed blinded histopathological analysis were performed. Results Two novel pathogenic ABCB4 variants were identified: c.620 T > G, p.(Ile207Arg) and c.2301dupT, p.(Thr768TyrfsTer26). Sub-phenotypes observed included low-phospholipid-associated cholelithiasis syndrome (LPAC), intrahepatic cholestasis of pregnancy (ICP), drug-induced cholestasis, idiopathic adulthood ductopenia, and adult PFIC3. Of note, 5/7 had presented with gallstone complications (4 meeting LPAC definition) and 4/6 females had a history of ICP. Considerable overlap was observed phenotypically and liver transplantation was required in 3/7 of patients. Histologically, cases generally demonstrated ductopenia of the smaller tracts, mild non-ductocentric portal inflammation, bilirubinostasis, significant copper-associated protein deposition, and varying degrees of fibrosis. Conclusions Adults with ABCB4 mutations may harbor a spectrum of cholestatic disease phenotypes and can progress to liver transplantation. We observed a distinct histological pattern which differs from classical biliary disease and describe two novel pathogenic ABCB4 variants. ABCB4 sequencing should be considered in patients with relevant cholestatic phenotypes and/or suggestive histology; accurate diagnosis can guide potential interventions to delay progression and inform family screening.
- 14 March 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (12) , 5551-5561
ABCB4 Mutations in Adults Cause a Spectrum Cholestatic Disorder Histologically Distinct from Other Biliary Disease
Background Mutations in the ABCB4 gene are associated with failure of bile acid emulsification leading to cholestatic liver disease. Presentations range from progressive familial intrahepatic cholestasis type 3 (PFIC3) in childhood, to milder forms seen in adulthood. Aims We sought to characterize adult disease with particular reference to histology which has been hitherto poorly defined. Methods Four unrelated adults (three female, mean age 39 years) and three sisters presenting with cholestatic liver disease in adulthood, associated with variants in the ABCB4 gene, were identified. Clinical review and detailed blinded histopathological analysis were performed. Results Two novel pathogenic ABCB4 variants were identified: c.620 T > G, p.(Ile207Arg) and c.2301dupT, p.(Thr768TyrfsTer26). Sub-phenotypes observed included low-phospholipid-associated cholelithiasis syndrome (LPAC), intrahepatic cholestasis of pregnancy (ICP), drug-induced cholestasis, idiopathic adulthood ductopenia, and adult PFIC3. Of note, 5/7 had presented with gallstone complications (4 meeting LPAC definition) and 4/6 females had a history of ICP. Considerable overlap was observed phenotypically and liver transplantation was required in 3/7 of patients. Histologically, cases generally demonstrated ductopenia of the smaller tracts, mild non-ductocentric portal inflammation, bilirubinostasis, significant copper-associated protein deposition, and varying degrees of fibrosis. Conclusions Adults with ABCB4 mutations may harbor a spectrum of cholestatic disease phenotypes and can progress to liver transplantation. We observed a distinct histological pattern which differs from classical biliary disease and describe two novel pathogenic ABCB4 variants. ABCB4 sequencing should be considered in patients with relevant cholestatic phenotypes and/or suggestive histology; accurate diagnosis can guide potential interventions to delay progression and inform family screening.
- 1 July 2021
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 5 (7) , 524-530
Juvenile haemochromatosis
- 1 July 2021
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 5 (7) , 524-530
Juvenile haemochromatosis
- 1 April 2021
- Published by Elsevier in Transplant Immunology
- Vol. 65, 101378
First report of liver transplantation in Blau syndrome: The challenges faced in this rare granulomatous liver disease
- 1 April 2021
- Published by Elsevier in Transplant Immunology
- Vol. 65, 101378
First report of liver transplantation in Blau syndrome: The challenges faced in this rare granulomatous liver disease
- Open Access
- 3 November 2020
- Published by Elsevier in Clinical Oncology
- Vol. 33 (1) , e90-E90
Prostate Ultrahypofractionation – Rising to Challenges Presents Opportunities in the COVID-19 Era
- 3 November 2020
- Published by Elsevier in Clinical Oncology
- Vol. 33 (1) , e90-E90
Open AccessProstate Ultrahypofractionation – Rising to Challenges Presents Opportunities in the COVID-19 Era
- 1 September 2019
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (7) , 2508-2509
Reply
- 1 September 2019
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (7) , 2508-2509
Reply